Race Oncology Begins Patient Enrollment at Second Site of RC220 Solid Tumor Clinical Trial

MT Newswires Live

Apr 22, 2025

Race Oncology (ASX:RAC) has opened patient enrollment at the second site of its phase one clinical trial for cancer drug candidate RC220, according to a Tuesday filing with the Australian bourse.

The second trial site is at the Central Coast Local Health District in New South Wales.

It will use ascending doses of RC220 in up to 33 patients in stage one to assess its safety, tolerability, pharmacokinetics, maximum tolerated dose in combination with doxorubicin, and effects on a range of clinical biomarkers.

Race Oncology is studying RC220 in combination with doxorubicin in patients with advanced solid tumors. The phase one trial will be conducted at multiple sites across Australia, Hong Kong, and South Korea, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2529284350"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2529284350\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2529284350?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-22 07:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529284350","market":"hk","top_or_hot":-1,"title":"Race Oncology Begins Patient Enrollment at Second Site of RC220 Solid Tumor Clinical Trial","media":"MT Newswires Live","content":"<html><body><p> Race Oncology (ASX:RAC) has opened patient enrollment at the second site of its phase one clinical trial for cancer drug candidate RC220, according to a Tuesday filing with the Australian bourse.</p><p>The second trial site is at the Central Coast Local Health District in New South Wales.</p><p>It will use ascending doses of RC220 in up to 33 patients in stage one to assess its safety, tolerability, pharmacokinetics, maximum tolerated dose in combination with doxorubicin, and effects on a range of clinical biomarkers.</p><p>Race Oncology is studying RC220 in combination with doxorubicin in patients with advanced solid tumors. The phase one trial will be conducted at multiple sites across Australia, Hong Kong, and South Korea, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Race Oncology Begins Patient Enrollment at Second Site of RC220 Solid Tumor Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRace Oncology Begins Patient Enrollment at Second Site of RC220 Solid Tumor Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-22 07:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Race Oncology (ASX:RAC) has opened patient enrollment at the second site of its phase one clinical trial for cancer drug candidate RC220, according to a Tuesday filing with the Australian bourse.</p><p>The second trial site is at the Central Coast Local Health District in New South Wales.</p><p>It will use ascending doses of RC220 in up to 33 patients in stage one to assess its safety, tolerability, pharmacokinetics, maximum tolerated dose in combination with doxorubicin, and effects on a range of clinical biomarkers.</p><p>Race Oncology is studying RC220 in combination with doxorubicin in patients with advanced solid tumors. The phase one trial will be conducted at multiple sites across Australia, Hong Kong, and South Korea, the filing said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XKO.AU","symbol_name":"标普/澳交所 300指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2529284350","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529284350","pubTimestamp":1745279337,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Race Oncology  has opened patient enrollment at the second site of its phase one clinical trial for cancer drug candidate RC220, according to a Tuesday filing with the Australian bourse.The second trial site is at the Central Coast Local Health District in New South Wales.It will use ascending doses of RC220 in up to 33 patients in stage one to assess its safety, tolerability, pharmacokinetics, maximum tolerated dose in combination with doxorubicin, and effects on a range of clinical biomarkers.Race Oncology is studying RC220 in combination with doxorubicin in patients with advanced solid tumors. The phase one trial will be conducted at multiple sites across Australia, Hong Kong, and South Korea, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XKO.AU":"标普/澳交所 300指数","RAC.AU":"RACE ONCOLOGY LTD","XJO.AU":"标普/澳交所 200指数","BK7067":"生物科技","BK7508":"医药生物股","XAO.AU":"标普/澳交所 普通股指数"},"translate_title":"Race Oncology在RC220实体瘤临床试验的第二个地点开始招募患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":0.78,"RAC.AU":0.9,"XAO.AU":0.78,"XJO.AU":0.78},"content_text":"Race Oncology (ASX:RAC) has opened patient enrollment at the second site of its phase one clinical trial for cancer drug candidate RC220, according to a Tuesday filing with the Australian bourse.The second trial site is at the Central Coast Local Health District in New South Wales.It will use ascending doses of RC220 in up to 33 patients in stage one to assess its safety, tolerability, pharmacokinetics, maximum tolerated dose in combination with doxorubicin, and effects on a range of clinical biomarkers.Race Oncology is studying RC220 in combination with doxorubicin in patients with advanced solid tumors. The phase one trial will be conducted at multiple sites across Australia, Hong Kong, and South Korea, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}